APOP stock is having a solid day with a gain of over 100% after Cellect Biotechnology Ltd. (NASDAQ:APOP) reported positive results from its ongoing Phase 1/2 clinical study of ApoGraft.
Solid NewsOne stock that has gone on an impressive rally this morning is Israel-based biotechnology company Cellect Biotechnology. It has emerged that the Data and Safety Monitoring Board (DSMB) has completed a review of Cellect’s product ApoGraft and made its recommendations. The review was done during the Phase 1 and Phase 2 studies of the product that are currently ongoing, and in its review, the ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.